Rezulin Linked to Liver Failure

Upon receiving reports, linking diabetes drug Rezulin with liver failure and death, the Food and Drug Administration (FDA) pulled Rezulin from the U.S. market in March, 2000. The drug is prescribed for treatment of Type 2 diabetes.

According to industry officials, an estimated 2 million Americans have tried Rezulin (also known by the generic name troglitazone) and more than 500,000 were taking it regularly when the product was recalled. Since its introduction in March 1997, Rezulin has ben linked to 90 cases of liver failure in 63 deaths and liver transplants. Many other people suffered cardiovascular injuries, including congestive heart failure. However, experts indicate that because these totals are based upon voluntary reports, they probably represent less than 10 percent of actual fatalities. Although a person's reaction to Rezulin is most often sudden and dramatic, those who have used Rezulin for more than 60 days are advised to check with their health professional, even if they are currently in good health and no longer taking this drug.

According to medical research and quantified medical experts, former Rezulin users have a significantly increased risk of developing Rezulin related illnesses. These conditions include:

Liver Injuries:

Cardiac Injuries:

Zimmerman Reed is pursuing claims of behalf of individuals where Rezulin use appears to have caused serious injury or death. If you wish to speak with an attorney about a possible Rezulin claim, please click here to send an e-mail or contact Ronald Goldser at our toll-free number, 1.800.755.0098.